Infections in Biological and Targeted Synthetic Drug Use in Rheumatoid Arthritis: Where do We Stand? A Scoping Review and Meta-analysis.
Barbara J M BergmansBiniyam Y GebeyehuEugène P van PuijenbroekKatrijn Van DeunBennett KleinbergJean-Luc MurkEsther de VriesPublished in: Rheumatology and therapy (2023)
The high heterogeneity and the inconsistency of potential predictors between studies show that we do not yet have a complete picture of infection risk in RA patients using biological or targeted synthetic drugs. Besides, we found non-serious infections outnumbered serious infections by a factor 10:1, but only a few studies have focused on their occurrence. Future studies should apply a uniform method of infectious adverse event reporting and also focus on non-serious infections and their impact on treatment decisions and quality of life.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- case control
- ejection fraction
- chronic kidney disease
- newly diagnosed
- cancer therapy
- disease activity
- risk assessment
- emergency department
- ankylosing spondylitis
- adverse drug
- patient reported outcomes
- current status
- systemic sclerosis
- climate change
- human health
- idiopathic pulmonary fibrosis